DOI QR코드

DOI QR Code

Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer

  • Yusof, Mastura Md ;
  • Abdullah, Nik MA ;
  • Sharial, MSN Mohd ;
  • Zaatar, Adel
  • Published : 2016.04.11

Abstract

Background: Between October 2012 and February 2015, 25 patients with metastatic colorectal cancer (mCRC) (mean age, $57.0{\pm}12.1years$) were granted access to aflibercept via the Aflibercept Named Patient Program at four centers. Materials and Methods: Here we reported the initial experience of aflibercept / FOLFIRI in combination. We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS). Results: The majority of the patients experienced gastrointestinal toxicity (grade 1-2), with diarrhea (52%), mucositis (52%), and nausea/vomiting (20%) being largely observed. Neutropenia (16%) and febrile neutropenia (8%) were common grade 3-4 hematological events. Aflibercept-related toxicity was managed as per practice guidelines. No grade 5 event was reported. Median PFS was 6.12 months (95% CI, 4.80-7.20) and OS was 12 months (95% CI, 9.80-14.18). The partial response (PR), stable disease (SD), and progressive disease (PD) rates were 25% (95% CI: 23.4-27.0), 37.5% (95% CI: 31.6-43.3), and 37.5% (95% CI: 22.5-52.5), respectively. Conclusions: Aflibercept/FOLFIRI can be administered safely in a second line setting to Malaysian patients with mCRC, as the AEs experienced were generally reversible and manageable. The safety and efficacy outcomes were consistent with those observed in Western populations.

Keywords

Aflibercept;metastatic colorectal cancer;FOLFIRI;gastrointestinal toxicity;safety;Malaysia

References

  1. Bai L, Zhang DS, Wu WJ, et al (2015). Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol, 32, 469.
  2. Chiron M, Bagley RG, Pollard J (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther, 13, 1636-44. https://doi.org/10.1158/1535-7163.MCT-13-0753
  3. Chiron M, Bagley RG, Pollard J, et al (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther, 13, 1636-44. https://doi.org/10.1158/1535-7163.MCT-13-0753
  4. Common Terminology Criteria for Adverse Events v4.0 (CTCAE 2009). U.S department of health and human services.
  5. Do K, Cao L, Kang Z, et al (2015). A phase II study of sorafenib combined with cetuximab in EGFR-expressing, KRAS-mutated metastatic colorectal cancer. Clin Colorectal Cancer, 14, 154-61. https://doi.org/10.1016/j.clcc.2015.02.007
  6. Garcia-Alfonso P, Ferrer A, Gil S, et al (2015). Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol, 10, 453-65. https://doi.org/10.1007/s11523-015-0362-0
  7. Grothey A, Van Cutsem E, Sobrero A, et al (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 38, 303-12.
  8. Jitawatanarat P, Wee W (2013). Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol, 4, 231-8.
  9. Lee JJ, Chu E (2014). Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer, 13, 135-44. https://doi.org/10.1016/j.clcc.2014.02.001
  10. Lim KG (2014). A review of colorectal cancer research in malaysia. Med J Malaysia, 69, 23-32.
  11. Majid N, Ghissassi I, Mrabti H, et al (2015). Bevacizumab in clinical practice. Gulf J Oncol, 1, 33-7.
  12. Malaysia cancer statistics- Data and figure (2007). National Cancer Registry Report.
  13. Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X (2013). The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol, 4, 72-81.
  14. Nishino M, Jagannathan JP, Ramaiya NH, et al (2010). Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgeno. 195, 281-9. https://doi.org/10.2214/AJR.09.4110
  15. Norwati D, Harmy MY, Norhayati MN, Amry AR (2014). Colorectal cancer screening practices of primary care providers: results of a national survey in Malaysia. Asian Pac J Cancer Prev, 15, 2901-4. https://doi.org/10.7314/APJCP.2014.15.6.2901
  16. Papadopoulos N, Martin J, Ruan Q (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15, 171-85. https://doi.org/10.1007/s10456-011-9249-6
  17. Passardi A, Nanni O, Tassinari D, et al (2015). Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol, 26, 1201-7. https://doi.org/10.1093/annonc/mdv130
  18. Patel A, Sun W (2014). Ziv-aflibercept in metastatic colorectal cancer. Biologics, 8, 13-25.
  19. Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol, 4, 68-70. https://doi.org/10.4251/wjgo.v4.i4.68
  20. Product Information (2012). ZALTRAP(R) intravenous injection, ziv-aflibercept intravenous injection. sanofi-aventis U.S.LLC (per FDA), Bridgewater, NJ.
  21. Syed YY, McKeage K (2015). Aflibercept: a review in metastatic colorectal cancer. Drugs, 75, 1435-45. https://doi.org/10.1007/s40265-015-0444-4
  22. Tang PA, Moore MJ (2013). Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and+ interpretations. Therap Adv Gastroenterol, 6, 459-73. https://doi.org/10.1177/1756283X13502637
  23. Van Cutsem E, Tabernero J, Lakomy R, et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol, 30, 3499-506. https://doi.org/10.1200/JCO.2012.42.8201
  24. Wong NA, Gonzalez D, Salto-Tellez M (2014). RAS testing of colorectal carcinoma-a guidance document from the association of clinical pathologists molecular pathology and diagnostics group. J Clin Pathol, 67, 751-7. https://doi.org/10.1136/jclinpath-2014-202467
  25. Yoshida M, Muro K, Tsuji A (2015). Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer, 51, 935-41. https://doi.org/10.1016/j.ejca.2015.03.007

Cited by

  1. Antineoplastics/folinic acid vol.1642, pp.1, 2017, https://doi.org/10.1007/s40278-017-27211-3
  2. Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy vol.22, pp.5, 2018, https://doi.org/10.1188/18.CJON.555-560